Publications:

A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy.

Molecular Therapy. Nucleic Acids

Wang, Hao H; Gao, Yuzhen Y; Vafaei, Somayeh S; Yu, Qiaoyan Q; Zhang, Jun J; Wang, Liangjing L

Publication Date: 2022-03-08

Variant appearance in text: HER2: A20N

PubMed Link: 35036055

Variant Present in the following documents:

• mmc2.pdf

View BVdb publication page

Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis.

Biomed Research International

Ma, Yao Y; Feng, Xiao-Fei XF; Yang, Wan-Xia WX; You, Chong-Ge CG

Publication Date: 2019

Variant appearance in text: ERBB2: A20N

PubMed Link: 31534952

Variant Present in the following documents:

• BMRI2019-1093815.pdf

View BVdb publication page

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.

Scientific Reports

Kiss, Bernhard B; Wyatt, Alexander W AW; Douglas, James J; Skuginna, Veronika V; Mo, Fan F; Anderson, Shawn S; Rotzer, Diana D; Fleischmann, Achim A; Genitsch, Vera V; Hayashi, Tetsutaro T; Neuenschwander, Maja M; Buerki, Christine C; Davicioni, Elai E; Collins, Colin C; Thalmann, George N GN; Black, Peter C PC; Seiler, Roland R

Publication Date: 2017-02-16

Variant appearance in text: ERBB2: A20N

PubMed Link: 28205537

Variant Present in the following documents:

View BVdb publication page